Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carvana Co (CVNA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Carvana (CVNA) trades at $65.83, down 1.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32B in 2025 and net income of $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and positive news highlights expansion into new-car sales and same-day delivery services. The stock shows improving cash flow trends, with operating cash flow reaching $1.04B in 2025.

Outlook: CVNA presents a mixed picture with robust revenue growth and profitability improvements offset by high valuation multiples and technical bearishness. Investment opportunity lies in continued operational scaling and market expansion, but risks include debt levels and competitive pressures. Analysts maintain a bullish consensus price target of $93.92, suggesting potential upside if execution continues.